Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from GSK

23andMe was once worth $6 billion. Now CEO Anne Wojcicki wants to buy it back for $43 million

Experts say the CEO’s second attempt to buy back the troubled DNA startup comes with a slew of corporate governance red flags.

Fortune

British pharma company GSK pauses diversity work citing Trump orders

London-based FTSE 100 firm reviewing its policies, saying it is obliged to comply because US is its No 1 market

The Guardian - UK

GSK could double CEO Emma Walmsley's pay to $27 million

The British pharma giant said Emma Walmsley's current pay could put off candidates for her eventual successor.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

GSK boss Emma Walmsley’s pay could rise to nearly £22m in three years’ time

UK pharmaceutical companies aim to put executive pay on par with US rivals’ but package will depend on share price

The Guardian - UK

Women hold almost 45% of seats on FTSE 100 boards, report says

New high tempered by dip in number of female CEOs at 100 biggest listed firms to fewer than 10 last year

The Guardian - UK

AstraZeneca, Whitehall, and a failed £450m deal for the next generation in vaccines. What went wrong?

When the pharma firm cancelled plans for a major expansion of its Merseyside plant last month, there was no shortage of questions – or blame – over responsibility

The Guardian - UK

Stock Market Sideways Amid Trump Tariff, Inflation Fears; Palantir, Google, Amazon Among Key Movers: Weekly Review

The stock market was up and down with Trump tariff fears in focus. Palantir led big earnings winners. Google and Amazon were losers.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Despite Profit Fallout, GSK Remains Optimist For 2031 Revenue Target Amidst Cancer Drug Sale Rise

GSK's oncology sales increased 98% in 2024, and reflects strong demand and potentially new launches or indications for cancer therapies.

International Business Times UK

Drug firm GSK delivers a syringe full of crowd-pleasers

Pharmaceuticals company’s higher dividend, upgrade to revenues and share buyback suggest its drugs pipeline is flowing nicely

The Guardian - UK

GSK Surges 8% After Bumping Its 2031 Outlook To North Of $50 Billion

GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 billion in sales.

Investors Business Daily

Novo Nordisk confident despite Trump tariff risk as sales of weight-loss jab soar

Europe’s biggest firm, whose sales of Wegovy almost doubled, feels it can ‘meet demands’ of US administration

The Guardian - UK

GSK lifts long-term sales targets on new drug pipeline

It came as the boss of the London-listed firm cheered an ‘excellent’ performance in 2024.

Evening Standard

The ‘super powerful’ tool behind a pharmaceutical giant’s global regulatory operation

When GSK’s regulatory teams needed help to sharpen up their project management, they turned to Smartsheet to reduce admin, increase collaboration and enhance performance overall

The Guardian - UK

Cancer vaccine being created by UK scientists could stop disease up to 20 years early

A new partnership between the University of Oxford and GSK aims to develop vaccines against cancer before develop

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

New cancer vaccine to stop disease before it takes hold in the body

Pharmaceutical giant GSK and the University of Oxford are creating a new cancer vaccine

Evening Standard

GSK and Oxford researchers to create cancer vaccine to stop disease developing

GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines.

The Guardian - UK

GSK signs £50m deal with Oxford University on cancer vaccines

Collaboration over at least three years aims to help understand how pre-cancerous cells develop

The Guardian - UK

Nvidia’s $465bn rout biggest in US stock market history, as DeepSeek sparks US tech sell-off – as it happened

ECB president Lagarde warns of ‘vicious circle’ if central bank independence is undermined

Get all your
news in one place.

100’s of premium titles.
One news app.

USA Today Sports Media Group

Gina Torres reflects on role in ‘Suits’ reunion commercial during Super Bowl LVIII

Actress Gina Torres reflects on her 'Suits' reunion commercial during Super Bowl LVIII w/ @EdEastonJr

USA Today Sports Media Group

Brooke Shields on the impact of her ‘Friends’ appearance after Super Bowl XXX

Chiefs Wire's @EdEastonJr spoke to iconic actress and author Brooke Shields at a women's empowerment brunch hosted by Donna Kelce.

The Guardian - UK

GSK to buy US cancer drug firm IDRx for up to $1.15bn

Massachusetts-based company is working on new treatments for gastrointestinal cancers

Evening Standard

GSK buys US-based rare cancer treatment developer for up to £1bn

The acquisition of IDRx will help GSK target a ‘major gap in the current standard of care’ related to gastrointestinal cancers.

The Guardian - UK

Pound slides to fresh 14-month low as stocks fall; rise in UK borrowing costs reverses – as it happened

Dollar jumps to over two-year high against major currencies as bets on US rate cuts recede; UK 30-year government bond yield eases after hitting fresh 27-year high

Barchart

3 Pharma Stocks to Buy as California Sounds the Alarm on Bird Flu Cases

The bird flu crisis is creating investment opportunities in the pharmaceutical sector, with Sanofi, GSK, and CSL Limited emerging as top picks.

MarketBeat

2 Small-Cap Stocks Set to Shine in a Bull Market

Small-cap growth-orientated stocks like HTCR and CVAC often outperform during bullish markets due to their sensitivity to improving economic conditions.

1 2 3 4 5

People

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.